Literature DB >> 20706749

Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody.

Scott A Yuzwa1, Anuj K Yadav, Yuliya Skorobogatko, Thomas Clark, Keith Vosseller, David J Vocadlo.   

Abstract

The microtubule-associated protein tau is known to be post-translationally modified by the addition of N-acetyl-D: -glucosamine monosaccharides to certain serine and threonine residues. These O-GlcNAc modification sites on tau have been challenging to identify due to the inherent complexity of tau from mammalian brains and the fact that the O-GlcNAc modification typically has substoichiometric occupancy. Here, we describe a method for the production of recombinant O-GlcNAc modified tau and, using this tau, we have mapped sites of O-GlcNAc on tau at Thr-123 and Ser-400 using mass spectrometry. We have also detected the presence of a third O-GlcNAc site on either Ser-409, Ser-412, or Ser-413. Using this information we have raised a rabbit polyclonal IgG antibody (3925) that detects tau O-GlcNAc modified at Ser-400. Further, using this antibody we have detected the Ser-400 tau O-GlcNAc modification in rat brain, which confirms the validity of this in vitro mapping approach. The identification of these O-GlcNAc sites on tau and this antibody will enable both in vivo and in vitro experiments designed to understand the possible functional roles of O-GlcNAc on tau.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706749     DOI: 10.1007/s00726-010-0705-1

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  40 in total

1.  Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates.

Authors:  David L Shen; Tracey M Gloster; Scott A Yuzwa; David J Vocadlo
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

2.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

Authors:  Scott A Yuzwa; Xiaoyang Shan; Matthew S Macauley; Thomas Clark; Yuliya Skorobogatko; Keith Vosseller; David J Vocadlo
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

Review 3.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

Review 4.  The emerging link between O-GlcNAcylation and neurological disorders.

Authors:  Xiaofeng Ma; He Li; Yating He; Junwei Hao
Journal:  Cell Mol Life Sci       Date:  2017-05-22       Impact factor: 9.261

Review 5.  Critical observations that shaped our understanding of the function(s) of intracellular glycosylation (O-GlcNAc).

Authors:  Natasha E Zachara
Journal:  FEBS Lett       Date:  2018-11-24       Impact factor: 4.124

Review 6.  The emerging link between O-GlcNAc and Alzheimer disease.

Authors:  Yanping Zhu; Xiaoyang Shan; Scott A Yuzwa; David J Vocadlo
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 7.  Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Authors:  Ilhan Akan; Stephanie Olivier-Van Stichelen; Michelle R Bond; John A Hanover
Journal:  J Neurochem       Date:  2017-11-20       Impact factor: 5.372

Review 8.  Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology.

Authors:  Krithika Vaidyanathan; Sean Durning; Lance Wells
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-14       Impact factor: 8.250

Review 9.  The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.

Authors:  Richard D Semba; Hu Huang; Gerard A Lutty; Jennifer E Van Eyk; Gerald W Hart
Journal:  Proteomics Clin Appl       Date:  2014-02-19       Impact factor: 3.494

Review 10.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.